美国介入性肿瘤学市场规模、份额、趋势分析报告：按程序、程序、应用、最终用途、细分预测，2025-2030

美国介入性肿瘤学市场趋势

预计 2024 年美国介入性肿瘤市场规模将达到 9.984 亿美元，2025 年至 2030 年复合年增长率为 8.17%。

由于癌症发生率的上升、微创手术技术的进步、介入性肿瘤学领域的投资增加以及老龄人口的增加，市场正在成长。

美国癌症盛行率的上升是推动市场成长的一个主要因素。根据美国癌症协会统计，美国新增癌症病例2,041,910例。在美国，预计 2025 年将出现 2,041,910 例新发癌症病例，同年预计将有 618,120 人死于癌症。化疗和放射线治疗等传统治疗方法通常具有明显的副作用，因此射频消融和微波消融等微创替代疗法越来越受欢迎。这些手术可局部破坏肿瘤，同时最大程度地减少对周围组织的损伤，从而改善患者的治疗效果并推动对介入性肿瘤学解决方案的需求。

介入性肿瘤学技术的持续进步正在提高这些手术的有效性和采用率。在这个市场运营的公司正专注于创新，将先进的产品推向市场，从而改善患者的治疗效果。例如，2023 年 9 月，Profound Medical 的 TULSA-PRO Thermal Boost 模组获得了美国FDA 的 510(k) 许可，该模组可以暂时提高前列腺特定区域的消融温度。热增强功能改善了 88% 前列腺癌病例的治疗效果，提高了治疗效果和工作流程效率。这些进步改善了临床结果并增加了介入性肿瘤学对医疗保健提供者的吸引力。

在美国，公共和私营部门对介入肿瘤学的投资不断增加，正在加速市场扩张。我们的开发、研发和创业投资投资支持推进精准肿瘤学的创新治疗方法的开发，并确保介入技术融入主流癌症治疗。例如，2024年12月，介入放射学会（SIR）基金会向四个研究计划颁发了150万美元的津贴。一项是开发新型肝细胞癌（HCC）模型的研究，另一项是利用基因亚型对HCC进行精准引导介入的研究。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国介入肿瘤学市场变数、趋势与范围

• 市场体系展望
  • 母市场展望
  • 相关/辅助市场展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 介入性肿瘤学市场分析工具
  • 产业分析—波特五力分析
  • PESTEL分析

第四章美国介入性肿瘤学市场（按程序、估计和趋势分析）

• 细分仪表板
• 美国介入性肿瘤学市场程序变化分析
• 2018-2030年美国介入性肿瘤学市场规模及趋势分析（依手术方式）
• 消融治疗
  • 射频消融术（RFA）
  • 微波消融（MWA）
  • 冷冻疗法
  • 雷射消熔
  • 不可逆电穿孔（IRE）
• 栓塞治疗
  • 经动脉化疗栓塞术（TACE）
  • 经动脉放射栓塞术（TARE）
• 切片检查技术
  • 芯针切片
  • 细针抽吸（FNA）
• 标靶治疗输送系统
  • 药物释放型珠
  • 放射栓塞术
  • 药物释放型支架
  • 可注射水凝胶和奈米颗粒
  • 其他标靶治疗系统
• 影像导引手术
  • 超音波引导
  • 电脑断层扫描指导
  • MRI导
  • 透视引导

第五章美国介入性肿瘤学市场（按程序、估计和趋势分析）

• 细分仪表板
• 美国介入性肿瘤学市场程序变化分析
• 美国介入性肿瘤学市场规模及趋势分析（依程序，2018-2030）
• 肿瘤消融
• 肿瘤切片检查
• 血管介入
• 安宁疗护

第六章美国介入性肿瘤材料市场的应用、估计与趋势分析

• 细分仪表板
• 美国介入性肿瘤学市场使用变化分析
• 美国介入性肿瘤学市场规模及应用趋势分析（2018-2030）
• 肝癌
• 肺癌
• 肾癌
• 摄护腺癌
• 乳癌
• 其他癌症

第七章美国介入肿瘤学市场最终用途、预测与趋势分析

• 细分仪表板
• 美国介入肿瘤学市场的最终用途差异分析
• 2018-2030年美国介入性肿瘤学市场规模及趋势分析（依最终用途）
• 医院
• 专科诊所
• 其他的

第八章 竞争态势

• 公司/竞争对手分类
• 战略地图
• 2024年企业市场分析
• 公司简介/上市公司
  • Medtronic
  • Boston Scientific Corporation
  • Johnson & Johnson（Ethicon）
  • Cook Medical
  • AngioDynamics Inc.
  • Stryker
  • Terumo Corporation
  • Siemens Healthineers（Varian）
  • Teleflex Incorporated
  • Profound Medical

U.S. Interventional Oncology Market Trends:

The U.S. interventional oncology market size was estimated at USD 998.4 million in 2024 and is projected to grow at a CAGR of 8.17% from 2025 to 2030. The market is growing due to increasing cancer prevalence, rising technological advancements in minimally invasive procedures, increasing investments in the field of interventional oncology, and the growing geriatric population in the country.

The rising prevalence of cancer in the U.S. is a major factor driving the market growth. According to the American Cancer Society, around. 2,041,910 new cancers are estimated to occur in the U.S. in 2025, while cancer is expected to cause 618,120 mortalities in the same year. As traditional treatments such as chemotherapy and radiation therapy often have significant side effects, minimally invasive alternatives such as radiofrequency ablation and microwave ablation are gaining popularity. These procedures offer localized tumor destruction with minimal damage to surrounding tissues, improving patient outcomes and driving demand for interventional oncology solutions.

Continuous technological advancements in interventional oncology are enhancing the effectiveness and adoption of these procedures. Companies operating in the market are focusing on innovation to introduce advanced products in the market, thereby improving patient outcomes. For instance, in September 2023, Profound Medical obtained 510(k) clearance from the U.S. FDA for its TULSA-PRO Thermal Boost module, which allows surgeons to temporarily elevate ablation temperatures in specific areas of the prostate. The Thermal Boost feature has led to improved treatment results in 88% of prostate cancer cases, thereby enhancing both efficacy and workflow efficiency. Such advancements improve clinical outcomes and increase the appeal of interventional oncology among healthcare providers.

The growing investment in interventional oncology from both public and private sectors is accelerating market expansion in the U.S. Government initiatives, research funding, and venture capital investments are supporting the development of innovative treatment modalities to improve precision oncology, ensuring that interventional techniques are integrated into mainstream cancer care. For instance, in December 2024, the Society of Interventional Radiology (SIR) Foundation awarded USD 1.5 million in grants to four research projects, two of which focus on interventional oncology. One study will develop a novel model of hepatocellular carcinoma (HCC), and the other will use genetic subtyping for precision-guided interventions for HCC.

U.S. Interventional Oncology Market Report Segmentation

This report forecasts revenue growth at country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. interventional oncology market report based on techniques, procedures, application, end use:

• Technique Outlook (Revenue, USD Million, 2018 - 2030)
• Ablation Therapies
  • Radiofrequency Ablation (RFA)
  • Microwave Ablation (MWA)
  • Cryoablation
  • Laser Ablation
  • Irreversible Electroporation (IRE)
• Embolization Therapies
  • Transarterial Chemoembolization (TACE)
  • Transarterial Radioembolization (TARE)
• Biopsy Techniques
  • Core Needle Biopsy
  • Fine Needle Aspiration (FNA)
• Targeted Therapy Delivery Systems
  • Drug-Eluting Beads
  • Radioembolization
  • Drug-Eluting Stents
  • Injectable Hydrogels and Nanoparticles
  • Other Targeted Therapy Systems
• Image-Guided Procedures
  • Ultrasound Guidance
  • CT Scan Guidance
  • MRI Guidance
  • Fluoroscopy Guidance
• Procedure Outlook (Revenue, USD Million, 2018 - 2030)
• Tumor Ablation
• Tumor Biopsy
• Vascular Interventions
• Palliative Care
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Liver Cancer
• Lung Cancer
• Kidney Cancer
• Prostate Cancer
• Breast Cancer
• Other Cancer
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Specialty Clinics
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Technique Segment
  • 1.2.2. Procedure Segment
  • 1.2.3. Application Segment
  • 1.2.4. End-use Segment
• 1.3. Information analysis
  • 1.3.1. Market formulation & data visualization
• 1.4. Data validation & publishing
• 1.5. Information Procurement
  • 1.5.1. Primary Research
• 1.6. Information or Data Analysis
• 1.7. Market Formulation & Validation
• 1.8. Market Model
• 1.9. Total Market: CAGR Calculation
• 1.10. Objectives
  • 1.10.1. Objective 1
  • 1.10.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. U.S. Interventional Oncology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Increasing technological advancements in minimally invasive procedures
    • 3.2.1.3. Growing geriatric population
    • 3.2.1.4. Increasing investments in the field of interventional oncology
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost associated with interventional oncology
    • 3.2.2.2. Requirement of highly skilled professionals
• 3.3. Interventional Oncology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Interventional Oncology Market: Technique Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. U.S. Interventional Oncology Market Technique Movement Analysis
• 4.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Technique, 2018 to 2030 (USD Million)
• 4.4. Ablation Therapies
  • 4.4.1. Ablation Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.2. Radiofrequency Ablation (RFA)
    • 4.4.2.1. Radiofrequency Ablation (RFA) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.3. Microwave Ablation (MWA)
    • 4.4.3.1. Microwave Ablation (MWA) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.4. Cryoablation
    • 4.4.4.1. Cryoablation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.5. Laser Ablation
    • 4.4.5.1. Laser Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4.6. Irreversible Electroporation (IRE)
    • 4.4.6.1. Irreversible Electroporation (IRE) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Embolization Therapies
  • 4.5.1. Embolization Therapies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.2. Transarterial Chemoembolization (TACE)
    • 4.5.2.1. Transarterial Chemoembolzation (TACE) market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5.3. Transarterial Radioembolization (TARE)
    • 4.5.3.1. Transarterial Radioembolization (TARE) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Biopsy Techniques
  • 4.6.1. Biopsy Techniques market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.2. Core Needle Biopsy
    • 4.6.2.1. Core Needle Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6.3. Fine Needle Aspiration (FNA)
    • 4.6.3.1. Fine Needle Aspiration (FNA) market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Targeted Therapy Delivery Systems
  • 4.7.1. Drug Delivery Systems market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.2. Drug-Eluting Beads
    • 4.7.2.1. Drug-Eluting Beads market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.3. Radioembolization
    • 4.7.3.1. Radioembolization market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.4. Drug-Eluting Stents
    • 4.7.4.1. Drug-Eluting Stents market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.5. Injectable Hydrogels and Nanoparticles
    • 4.7.5.1. Injectable Hydrogels and Nanoparticles market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7.6. Other Targeted Therapy Systems
    • 4.7.6.1. Other Targeted Therapy Systems market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.8. Image-Guided Procedures
  • 4.8.1. Image-Guided Procedures market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.2. Ultrasound Guidance
    • 4.8.2.1. Ultrasound Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.3. CT Scan Guidance
    • 4.8.3.1. CT Scan Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.4. MRI Guidance
    • 4.8.4.1. MRI Guidance market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8.5. Fluoroscopy Guidance
    • 4.8.5.1. Fluoroscopy Guidance market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Interventional Oncology Market: Procedures Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. U.S. Interventional Oncology Market Procedures Movement Analysis
• 5.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Procedures, 2018 to 2030 (USD Million)
• 5.4. Tumor Ablation
  • 5.4.1. Tumor Ablation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Tumor Biopsy
  • 5.5.1. Tumor Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Vascular Interventions
  • 5.6.1. Vascular Interventions market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Palliative Care
  • 5.7.1. Palliative Care market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Interventional Oncology Materials Market: Applications Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. U.S. Interventional Oncology Market Applications Movement Analysis
• 6.3. U.S. Interventional Oncology Market Size & Trend Analysis, by Applications, 2018 to 2030 (USD Million)
• 6.4. Liver Cancer
  • 6.4.1. Liver Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Lung Cancer
  • 6.5.1. Lung Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Kidney Cancer
  • 6.6.1. Kidney Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Prostate Cancer
  • 6.7.1. Prostate Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Breast Cancer
  • 6.8.1. Breast Cancer market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Other Cancer
  • 6.9.1. Other Cancer market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. U.S. Interventional Oncology Market: End-use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. U.S. Interventional Oncology Market End Use Movement Analysis
• 7.3. U.S. Interventional Oncology Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.5. Specialty Clinics
  • 7.5.1. Specialty Clinics market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Company/Competition Categorization
• 8.2. Strategy Mapping
• 8.3. Company Market Position Analysis, 2024
• 8.4. Company Profiles/Listing
  • 8.4.1. Medtronic
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Boston Scientific Corporation
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Johnson & Johnson (Ethicon)
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Cook Medical
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. AngioDynamics Inc.
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Stryker
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Terumo Corporation
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Siemens Healthineers (Varian)
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Teleflex Incorporated
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Profound Medical
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. interventional oncology market by modality, 2018 - 2030 (USD Million)
• Table 4 U.S. interventional oncology market by technology, 2018 - 2030 (USD Million)
• Table 5 U.S interventional oncology market by mobility, 2018 - 2030 (USD Million)
• Table 6 U.S interventional oncology market by end use, 2018 - 2030 (USD Million)
• Table 7 Participant's overview
• Table 8 Financial performance
• Table 9 Key companies undergoing expansions
• Table 10 Key companies undergoing acquisitions
• Table 11 Key companies undergoing collaborations
• Table 12 Key companies launching new products
• Table 13 Key companies undergoing partnerships
• Table 14 Key companies undertaking other strategies

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market formulation & validation
• Fig. 4 U.S. interventional oncology market: Market outlook
• Fig. 5 U.S. interventional oncology market: Segment outlook
• Fig. 6 U.S. interventional oncology market: Competitive landscape outlook
• Fig. 7 Parent market outlook
• Fig. 8 U.S. interventional oncology market driver impact
• Fig. 9 U.S. interventional oncology market restraint impact
• Fig. 10 U.S. interventional oncology market: Technique outlook and key takeaways
• Fig. 11 U.S. interventional oncology market: Technique movement analysis
• Fig. 12 Ablation therapies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 13 Radiofrequency Ablation (RFA) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 14 Microwave Ablation (MWA) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 15 Cryoablation market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 16 Laser Ablation market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 17 Irreversible Electroporation (IRE) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 18 Embolization therapies market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 19 Transarterial Chemoembolization (TACE) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 20 Transarterial Radioembolization (TARE) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 21 Biopsy rechniques market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 22 Core needle biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 23 Fine Needle Aspiration (FNA) market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 24 Targeted therapy delivery systems market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 25 Drug-eluting beads market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 26 Radioembolization market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 27 Drug-eluting stents market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 28 Injectable Hydrogels and Nanoparticles market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 Other targeted therapy systems market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 Image-guided procedures market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 ultrasound guidance market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 CT scan guidance market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 MRI guidance market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 Fluoroscopy Guidance market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 U.S. interventional oncology market: Procedures outlook and key takeaways
• Fig. 36 U.S. interventional oncology market: Procedures movement analysis
• Fig. 37 Tumor ablation market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Tumor biopsy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Vascular interventions market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Palliative care market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 U.S. interventional oncology market: Applications outlook and key takeaways
• Fig. 42 U.S. interventional oncology market: Applications movement analysis
• Fig. 43 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Other cancer market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 U.S. interventional oncology market: End-use outlook and key takeaways
• Fig. 50 U.S. interventional oncology market: End-use movement analysis market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Specialty clinics market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 Others market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Other market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Heat map analysis
• Fig. 56 Market participant categorization
• Fig. 57 U.S. interventional oncology market share analysis, 2024
• Fig. 58 Strategy framework